



Memorandum

Date: December 19, 2025
To: Healthcare Practitioners
From: Insured Health Services
Subject: Formulary Updates December 2025

Dear Healthcare Practitioner,

Remicade (Infliximab)

- All client's on Remicade need to be moved to biosimilars as of March 1, 2026.
- There will be no more extensions granted past that date.

Exception Criteria:

Please see [Yukon Drug Formulary](#) for Criteria.

Fremanezumab (Ajovy)

- Effective November 18, 2025, Fremanezumab (Ajovy) will be added to the Yukon drug plan formulary as an exception drug for Pharmacare program.
- **Please note only eligible and registered program beneficiaries will be covered for the drug.**

- **Approval period:** Initial Approval Period: 6 Months

Renewal Approval Period: 1 year

Exception Criteria:

Please see [Yukon Drug Formulary](#) for Criteria.

Pessary

- Effective as of April 3, 2025, Pharmacare will approved Pessaries for urinary incontinence and pelvic organ prolapse.
- Approval is for two pessaries as a regular benefit and if a third is needed it may be approved on a case-by-case basis.
- A maximum of \$100 per pessary will be funded by the Pharmacare program
- Funding will be considered every 3 years

Annual Price change has been completed and will be effective as of November 19, 2025.

We have clarified the Aflivu criteria and corrected some wording. Please see [Yukon Drug Formulary](#) for more information.

Update regarding the medication APO-Colesevelam has been delisted from our formulary, for future claims please bill the Brand Name (Lodalis).

Contact Information:

Chronic Disease and Disability Benefits: 867-667-5092

Pharmacare and Extended Benefits: 867-667-5403 or 867-667-8494

Insured Health Services | Chronic Diseases and Disability Benefits | Pharmacare and Extended Benefits